Individual Bioequivalence Interim Approach Proposed To Gather More Data
An expert panel assembled by FDA is proposing that the agency adopt an interim approach to new bioequivalence methods, panel member Leslie Benet, PhD, University of California(San Francisco, told an American Association of Pharmaceutical Scientists workshop held March 16-18 in Arlington, Va.
You may also be interested in...
FDA is planning to conduct a two-year evaluation of its recommended replicate design method to determine whether a transition away from average bioequivalence criterion and towards individual and population BE criteria should occur.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011